Over 200 GLP1 obesity programs are in development today. More than 300 PD1/PDL1 cancer programs exist. Greater than 150 programs target each of CD19 and KRAS. Therapeutic crowding has ratcheted up the competitive intensity in biotech to new levels. While The post Biotech Wisdom Of The Crowds: Competition And Capitalism appeared first on LifeSciVC.
